News & Events about Cassava Sciences Inc.
Figure 1
Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease.
Figure 2
Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease.
ADAS-Cog mean scores changed...
AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. We mourn profoundly the passing of a cherished...
PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating Cassava Sciences, Inc. (Cassava or the Company) (NASDAQ: SAVA) on behalf of the Companys long-term investors. On November 17, 2021, The Wall Street Journal reported that ...
Globe Newswire
2 months ago
Outside Biostatisticians with Specific Expertise in Alzheimers Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06, 2022...
Globe Newswire
2 months ago
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences), a clinical-stage biotechnology company focused on Alzheimers disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of ...